AF
FBRX icon

Amalgamated Financial’s Forte Biosciences FBRX Stock Holding History

Amalgamated Financial’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3K Buy
+77
New +$2.91K ﹤0.01% 2979

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's FBRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Forte Biosciences (FBRX) in Q1 2022: 77 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2979 among its holdings.

52 funds tracked by Wall St. Rank hold FBRX as of Q1 2022.

  • Amalgamated Financial held 77 shares of Forte Biosciences worth $3K as of Q1 2022.
  • Forte Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Forte Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2979 holding.
  • 52 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.